Following a short presentation, participants will take part in a guided roundtable discussion exploring how to successfully transition AAV programmes from adherent to suspension-based manufacturing while maintaining analytical robustness, comparability, and regulatory confidence. This interactive session will focus on practical lessons learned from real process transitions, highlighting how manufacturing decisions directly shape analytical strategy, cost of goods, and long-term scalability for eye-targeted gene therapies.

• Lessons from switching adherent to suspension-based AAV processes to increase output and reduce cost per dose
• Understanding how analytical strategies must evolve to support process changes
• Highlighting comparability strategy pain points for process changes